Derbeneva S.A., Pogozheva A.V., Shmeleva S.V., Sabanchieva Zh.Kh.
Unifactorial prediction of the risks of development and progression of cardiovascular diseases
|
№4 / 2024
|
De V.A., Batyukina S.V., Kochetkov A.I., Klepikova M.V., Konik V.A., Ostroumova O.D.
Cognitive status of patients with coronary artery disease and concomitant atrial fibrillation
|
№4 / 2024
|
Trukhan D.I., Sulimov A.F., Trukhan L.Yu.
Orofacial pain as a manifestation of myocardial ischemia
|
№1 / 2024
|
B.G. Iskenderov, A.V. Zaitseva, I.N. Mozhzhukhin, M.G. Ivanchukova
Impact of coronary artery stenting on the course of chronic kidney disease in patients with stable angina
|
№13 / 2022
|
A.I. Kochetkov (1), A.P. Pereverzev (1), O.D. Ostroumova (1), D.G. Gusenbekova (1), R.R. Romanovsky (2), N.A. Shatalova (3)
The choice of antianginal therapy for polymordib patients with coronary artery disease and type 2 diabetes mellitus: the benefits of trimetazidine
|
№3 / 2021
|
O.D. Ostroumova (1, 2), A.I. Kochetkov (1), S.V. Batyukina (1), N.L. Lyakhova (3)
Approaches to choosing a direct oral anticoagulant in the treatment of polymorbid patients with atrial fibrillation
|
№3 / 2020
|
N.P. Lyamina (1), A.V. Kosareva (2)
The justified position of rosuvastatin in therapeutic practice
|
№9 / 2019
|
M.V. Ezhov
EVOLOUCUMAB - NEW HYPOLIDEPHEMIC AGENT FOR CARDIOVASCULAR RISK REDUCTION
|
№20 / 2017
|
E.A. Kolomiets, N.S. Besova, I.A. Kurmukov, Sh.R. Kashia, M.N. Narimanov, A.P. Sandomirskaya
CARDIOVASCULAR TOXICITY OF FLUOROPIRYMIDINES
|
№18 / 2017
|
M.V. Ezhov, E.V. Sorokin
SAFETY AND EFFICACY OF LONG-TERM THERAPY WITH HIGH DOSES OF ATORVASTATIN
|
№15 / 2017
|
M.E. Statsenko, S.V. Turkina, I.A. Tyshchenko, S.V. Fabritskaya, L.V. Poletaeva
POTENTIALS FOR THE DRUG CORRECTION OF SECONDARY MITOCHONDRIAL DYSFUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE AND COMORBID PATHOLOGY
|
№6 / 2017
|
A.F. Verbovoy, L.A. Sharonova
DIABETES MELLITUS AND CORONARY ARTERY DISEASE: FEATURES OF CLINICAL MANIFESTATION AND TREATMENT.
|
№16 / 2016
|